16
Participants
Start Date
July 29, 2009
Primary Completion Date
September 22, 2009
Study Completion Date
September 22, 2009
GSK573719
GSK573719 is a long-acting, inhaled, muscarinic receptor antagonist or anticholinergic bronchodilator. GW642444 is a potent and selective long-acting beta-2 agonist. Both are in development for once daily monotherapies for the treatment of COPD. In this study, their effects are investigated following individual and concurrent administration.
GSK Investigational Site, Randwick
Lead Sponsor
GlaxoSmithKline
INDUSTRY